Solid Biosciences is trading 10.06% down at $6.04, with no fresh company-specific announcement or catalyst identified for October 13, 2026. - A market-news listing likewise reported no new company-specific catalysts during the session. - The supplied sector context puts XBI down 2.01%, while broader major indexes were only modestly lower. This supports a sector explanation but does not establish the cause of the stock’s larger decline.